Navigation Links
Portola Pharmaceuticals Announces Positive Phase II Results for,PRT054021 for Prevention of Venous Thromboembolism Following Total,Knee Replacement Surgery

Data to be Presented at the XXI Congress of the International Society on Thrombosis and Haemostasis

SOUTH SAN FRANCISCO, Calif., April 04, 2007 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced that it has received positive results from EXPERT, a Phase II study of its oral Factor Xa inhibitor, PRT054021, for the prevention of venous thromboembolism (VTE) following total knee replacement (TKR) surgery. Based on these results, Portola will advance PRT054021 into further clinical testing.

"Successful completion of EXPERT is a significant achievement and is the result of many years of work by the Portola team in the field of anticoagulants," said Charles Homcy, M.D., CEO of Portola. "We are pleased that the results of this study are consistent with our predicted therapeutic dose range for PRT054021."

EXPERT (Evaluation of the Factor Xa Inhibitor, PRT054021, against Enoxaparin in a Randomized Trial for the Prevention of Venous Thromboembolic Events after Unilateral Total Knee Replacement) enrolled over 200 patients at 20 medical centers in the United States and Canada in a randomized, active comparator, parallel-group trial. Patients were randomized to receive one of two oral doses of PRT054021, or Lovenox(R) (enoxaparin) given as a subcutaneous injection. The treatment period was for ten to fourteen days after surgery, at which time a venogram was obtained to determine the presence of VTE.

The EXPERT steering committee, which includes a group of leading physicians and orthopedic surgeons with significant experience in conducting clinical trials involving novel anticoagulants, determined that EXPERT met its objectives: PRT054021 appeared effective and safe at the two doses studied, and the results support advancing the compound into further clinical trials. Data from EXPERT will be presented at the XXI Congress of the International Society on Thrombosis and Haemostasis in Geneva, Swi
'"/>




Page: 1 2 3

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
3. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:9/30/2014)... The Eastern European medical device industry is ... well as new medical-device manufacturers are constantly trying to ... ways to reduce the cost incurred for placing their ... the effective means to achieve this target. This research ... European and provides profiles of key distributors in ...
(Date:9/30/2014)... Sept. 30, 2014 Passport Health, one of ... , has launched FluFree.com, a website designed to promote, ... For 20 years, Passport Health has provided its ... The launch of FluFree.com is designed to address the ... number of people who actually chose to get vaccinated. ...
(Date:9/30/2014)... MUNSTER, Ind. , Sept. 30, 2014  The orthopedic ... ranked the nation,s No. 6 orthopedic group by US ... for Active Adults," a series of free, public seminars ... from all over the world come to see the ... replacement procedures are now available at Munster Specialty Surgery ...
Breaking Medicine Technology:Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2
... Feb. 27, 2012  GP Strategies Corporation (NYSE: ... provider of sales and technical training, e-Learning solutions, management ... Greenberg and CFO Sharon Esposito-Mayer will speak at the ... 2012, at 10:55 a.m. ET. The conference will be ...
... 27, 2012 Nektar Therapeutics (Nasdaq: NKTR ) ... its new oral opioid analgesic molecule, at the 2012 American ... a novel mu-opioid agonist molecule, which was designed to have ... the attractiveness of the molecule as a target of abuse ...
Cached Medicine Technology:Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 2Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 3Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 4Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 5Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 6Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 7Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 8Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 9Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 10
(Date:10/1/2014)... October 01, 2014 The Oliver ... a new Other-Sonic Ultrasound Gel lawsuit web ... about the litigation surrounding the 2011 Pseudomonas aeruginosa ... in Royal Oak, Michigan, which was ultimately traced ... is representing William Beaumont patients who allegedly became ...
(Date:10/1/2014)... MI (PRWEB) October 01, 2014 To help ... wellness center , Cutler Integrative Medicine, is detailing several tips ... , According to Dr. Cutler, women should start ... quality time for yourself that will help ‘center’ yourself for ... of stress,” he says. , Other health and fitness ...
(Date:9/30/2014)... third of medical and nursing students in developing countries ... countries after graduation, while less than one fifth of ... are needed most, according to a new study. , ... the current outbreak of Ebola in western Africa. The ... of the world,s poorest countries (Guinea, Sierra Leone and ...
(Date:9/30/2014)... carbon emissions will reduce other harmful air pollution ... a new study released today. The research shows ... the final Clean Power Plan, the power plant ... hospitalizations, and hundreds of heart attacks in the ... Health Co-benefits of Carbon Standards for Existing Power ...
(Date:9/30/2014)... stranger to the children of Tanzania. What is rare ... services, including reliable diagnosis and evidence-based treatments. There is ... in Swahili, a major language of the region. In ... and the University of Georgia (UGA) describe a culturally ... in the country and found to be effective for ...
Breaking Medicine News(10 mins):Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 2Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 3Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 4Health News:In Recognition of National Women’s Health and Fitness Day, Cutler Integrative Medicine Details Tips for Living a Healthier and Happier Life 2Health News:Developing countries should enroll medical and nursing students from rural areas 2Health News:Developing countries should enroll medical and nursing students from rural areas 3Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4
... There is an increasing number of HIV cases reported among ... by the Centre for disease control and prevention (CDC) and ... sharing and using the same needle up to 15 times ... ,The researchers are very worried and discussed about ...
... have found that a protein known for driving the ... restoring the ability of neurons to regenerate // , ... damage or neurological diseases like Alzheimers., ,"The finding ... proliferating cancer could also potentially be used to regrow ...
... help people lose weight, will be launched in the UK.This ... that controls //the desire to over-eat and it has been ... worldwide to have access to the medication. ,It ... loss by blocking the brain's craving signals, thereby suppressing the ...
... vaccination experts have written an open letter in the Scotsman ... the rumors// that MMR Vaccine was linked to autism. ... taken, the UK could face a serious situation with outbreaks ... questions of "any association between MMR and autism" should be ...
... contraceptive pill intended for consumption without a break is ... The pill, named Anya, manufactured by Wyeth Pharmaceuticals, is ... to give a merry slip to the monthly period! ... is undergoing a testing period marked by extensive clinical ...
... of transplant surgeries, doctors are rethinking on the guidelines ... (AHEC) is deliberating //over the permission for medical procedures ... on the ventilator, with a motive to remove organs ... the issue of removal of organs from the patient ...
Cached Medicine News:Health News:Wonder Drug For Weight Loss Launched In UK 2
Portable shields for your safety and convenience....
Provide 1.5mm protection throughout. Six durable, attractive vinyl coverings are available. Lead glass window factory installed. Larger window available....
Swing-Arm™ Scatter Shield® provides lower extremity protection for personnel close to the tube. 24"Wx32"L lead shield swings 180 along table. Ideal for cardiac cath, special studies, electr...
Front Protection with attached Belt Guard, Built-in Back Support; Buckle Closure...
Medicine Products: